HC Wainwright Decreases Earnings Estimates for Cytosorbents

Cytosorbents Corporation (NASDAQ:CTSO) – Equities researchers at HC Wainwright decreased their Q1 2027 earnings per share estimates for shares of Cytosorbents in a report released on Friday, August 7th. HC Wainwright analyst S. Lee now expects that the medical research company will earn $0.00 per share for the quarter, down from their previous forecast of $0.01. The consensus estimate for Cytosorbents’ current full-year earnings is ($0.19) per share. HC Wainwright also issued estimates for Cytosorbents’ Q2 2027 earnings at $0.00 EPS, Q3 2027 earnings at $0.01 EPS and Q4 2027 earnings at ($0.01) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cytosorbents in a report on Monday, July 6th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $5.38.

Cytosorbents Price Performance

Shares of NASDAQ CTSO opened at $0.36 on Monday. The company has a debt-to-equity ratio of 4.70, a quick ratio of 0.81 and a current ratio of 1.09. The firm has a fifty day moving average of $0.40 and a 200 day moving average of $0.55. The firm has a market cap of $22.75 million, a PE ratio of -1.25 and a beta of 1.39. Cytosorbents has a one year low of $0.35 and a one year high of $1.22.

Cytosorbents (NASDAQ:CTSO) last announced its earnings results on Thursday, August 6th. The medical research company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.03). Cytosorbents had a negative net margin of 48.94% and a negative return on equity of 309.53%. The business had revenue of $9.63 million for the quarter, compared to analysts’ expectations of $9.38 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CTSO. Citadel Advisors LLC raised its position in shares of Cytosorbents by 127.3% in the third quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock valued at $61,000 after buying an additional 36,790 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Cytosorbents by 149.2% in the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock worth $63,000 after buying an additional 37,519 shares in the last quarter. Vanguard Group Inc. boosted its position in Cytosorbents by 3.7% during the third quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock worth $2,059,000 after acquiring an additional 79,535 shares during the last quarter. Avenir Corp grew its stake in Cytosorbents by 2.9% during the 4th quarter. Avenir Corp now owns 5,230,099 shares of the medical research company’s stock valued at $3,343,000 after acquiring an additional 147,261 shares in the last quarter. Finally, CIBC Bancorp USA Inc. acquired a new stake in Cytosorbents in the 3rd quarter valued at about $161,000. Hedge funds and other institutional investors own 32.87% of the company’s stock.

Insider Buying and Selling at Cytosorbents

In other news, CEO Phillip P. Chan bought 251,136 shares of the firm’s stock in a transaction dated Friday, June 12th. The shares were acquired at an average price of $0.40 per share, for a total transaction of $100,454.40. Following the completion of the transaction, the chief executive officer directly owned 1,734,099 shares in the company, valued at $693,639.60. The trade was a 16.93% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 7.80% of the stock is currently owned by company insiders.

Cytosorbents Company Profile

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.